Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ose Pharma International SA | Paris | Healthcare | Biotechnology & Medical Research | €210.57M | 4.5x | 0.02 | €9.67 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.2% Upside | Upgrade to Pro+ | |
Genfit | Paris | Healthcare | Biotechnology & Medical Research | €257.51M | 11.5x | 0.07 | €5.17 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Theraclion SA | Paris | Healthcare | Healthcare Equipment & Supplies | €17.45M | -2.2x | €0.38 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Courtois | Paris | Real Estate | Real Estate Operations | €9.41M | -32.8x | 1.21 | €130 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gaztransport et Technigaz SA | Paris | Energy | Oil & Gas Related Equipment and Services | €4.97B | 17.2x | 0.18 | €133.80 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.1% Upside | Upgrade to Pro+ | |
Orinoquia Real Estate SOCIMI | Paris | Real Estate | Residential & Commercial REITs | €19.98M | 26.4x | €1.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hydro Exploitations | Paris | Utilities | Electrical Utilities & IPPs | €13.53M | 9.3x | 0.01 | €110 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DBV Technologies | Paris | Healthcare | Pharmaceuticals | €76M | -0.9x | -0.07 | €0.79 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nanobiotix | Paris | Healthcare | Biotechnology & Medical Research | €184.88M | -5x | -0.11 | €3.90 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abivax SA | Paris | Healthcare | Biotechnology & Medical Research | €620.18M | -3.1x | -1.89 | €9.80 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |